Regulatory Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation Pharmaceutical Business ReviewAuvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication.NeuroscienceRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaceutical Business Review Auvelity is a first-in-class therapy targeting both N-methyl D-aspartate (NMDA) and sigma-1 receptors for this indication. Neuroscience Read full story Post navigation Previous: LEO Pharma to acquire gene therapy company ReplayNext: FDA’s ODAC delivers one loss, one win for AstraZeneca Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
